Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.
Isolated hepatic perfusion (IHP) involves a method of complete vascular isolation of the liver to allow treatment of liver tumours with toxic systemic doses. The recent clinical studies mainly employed IHP with melphalan with or without tumour necrosis factor-alpha (TNF-alpha) and mild hyperthermia. The results of these studies show that high response rates and high survival rates can be achieved by IHP. In this article, the current status, recent developments and future perspectives of IHP are discussed.
Rothbarth
J
J
Department of Surgery, K6-R, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Tollenaar
R A E M
RA
Schellens
J H M
JH
Nortier
J W R
JW
Kool
L J Schultze
LJ
Kuppen
P J K
PJ
Mulder
G J
GJ
van de Velde
C J H
CJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D015179:Colorectal Neoplasms; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008558:Melphalan / Q000008:administration & dosage / Q000493:pharmacokinetics; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000493:pharmacokinetics
D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan